A Comprehensive Care Plan for Pediatric Patients With Vaso-Occlusive Crises
NCT02698761 · Status: TERMINATED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 3
Last updated 2018-05-03
Summary
Sickle cell disease (SCD) is the most common inherited blood disorder affecting 80,000 to 90,000 individuals in the United States.\[10\] There are 13,000 hospital admissions for a sickle cell crises, costing $448 million dollars annually.\[10\] In our hospital, the sickle cell population is known to have some of the longest length of stays. Between October 2014 and September 2015, there were 89 admissions for a vaso-occlusive crisis with an average length of stay of 6 days and 12 admissions greater than 10 days and 5 admissions greater than 20 days.
We propose to evaluate the feasibility of the new CPP in a pilot randomized control trial to determine if pain and length of stay can be reduced in patients with sickle cell disease. We also propose to evaluate a sleep regimen to determine if this can reduce the hospital stay and help with pain. We hypothesize increased physical activity and proper sleep, as implemented in the CPP, are correlated with decreased hospital length of stay and decreased pain. Additionally, we believe that creating a standardized nighttime environment at the hospital will help the children stay in their circadian rhythm thus promoting improved sleep and a more effective inpatient disease management.
Conditions
- Sickle Cell Disease
- Sickle Cell Crisis
- Vaso-Occlusive Crises
Interventions
- OTHER
-
Comprehensive Care Plan
Care Plan 1. Patient Controlled Analgesia (PCA). PCA will be initiated and managed at the discretion of the Pain Management team. 2. Other Medications. All medications will be given during daytime hours, if possible. 3. Pain Psychology. 4. Physical Therapy. Patient is expected to spend time out of bed by Day 2 participating in light activity. 5. Sleep Hygiene. Patient sleeps between the hours of 10 PM and 5 AM daily. Window blinds open by 8 AM. Patient must be awake and ready to participate in therapy by 9 AM. 6. Extracurricular. TV, phone, computer, and video games only between hours of 4-9 PM (computer okay outside of hours only for school work). 7. Other. Patient will eat meals during regular daytime hours (e.g. breakfast consumed before 9 am) and shower daily.
Sponsors & Collaborators
-
Phoenix Children's Hospital
collaborator OTHER -
Valley Anesthesiology Consultants
lead OTHER
Study Design
- Allocation
- RANDOMIZED
- Purpose
- SUPPORTIVE_CARE
- Masking
- SINGLE
- Model
- PARALLEL
Eligibility
- Min Age
- 12 Years
- Max Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2016-04-30
- Primary Completion
- 2018-03-31
- Completion
- 2018-03-31
Countries
- United States
Study Locations
More Related Trials
-
Different Treatment Modalities in the Management of the Painful Crisis in Pediatric Sickle- Cell Anemia
NCT04301336 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Hydroxyurea to Prevent Brain Injury in Sickle Cell Disease
NCT01389024 ·Status: COMPLETED ·Phase: PHASE2
-
Is the Preoperative Preparation of Sickle Cell Patients Optimal: Assessment of Practices and Post-operative Complications
NCT04264871 ·Status: UNKNOWN
-
Inhaled Nitric Oxide for Pediatric Painful Sickle Crisis
NCT00142051 ·Status: TERMINATED ·Phase: PHASE2
-
Evaluation of the Lung Capillary Blood Volume in Children With Sickle Cell Disease
NCT00560261 ·Status: COMPLETED ·Phase: PHASE3
-
Cooperative Assessment of Late Effects for SCD Curative Therapies
NCT05153967 ·Status: RECRUITING
-
The Use of Warmed Saline in Vaso-occlusive Episodes
NCT02316366 ·Status: COMPLETED ·Phase: NA
-
Comparison of Patient Centered Outcomes for People With Sickle Cell Disease in the Acute Care Setting
NCT02411396 ·Status: COMPLETED
-
Stroke Prevention in Sickle Cell Anemia (STOP 1)
NCT00000592 ·Status: COMPLETED ·Phase: PHASE3
-
Epidemiology of Silent and Overt Strokes in Sickle Cell Disease
NCT03376893 ·Status: ACTIVE_NOT_RECRUITING
-
Prevention of Cerebral Infarction in Sickle Cell Anemia - Comprehensive Sickle Cell Center
NCT00005327 ·Status: COMPLETED
-
Morphine Clearance and Glomerular Filtration in Sickle Cell Patients in Crisis in Intensive Care
NCT07246265 ·Status: RECRUITING ·Phase: NA
-
Silent Cerebral Infarct Transfusion Multi-Center Clinical Trial
NCT00072761 ·Status: COMPLETED ·Phase: PHASE3
-
Safety and Efficacy of Sodium Nitrite in Sickle Cell Disease
NCT01033227 ·Status: TERMINATED ·Phase: PHASE1/PHASE2
-
Telemedicine for Children With Sickle Cell Disease
NCT05087303 ·Status: ACTIVE_NOT_RECRUITING ·Phase: NA
-
Study of Blood Platelets in Sickle Cell Disease
NCT00226083 ·Status: WITHDRAWN
-
Steroid Treatment for Sickle Cell Pain Crisis
NCT00263562 ·Status: TERMINATED ·Phase: PHASE3
-
Metabolic and Hemodynamic Reserve in Pediatric SCA
NCT04406818 ·Status: RECRUITING ·Phase: NA
-
Dense Red Blood Cells in Sickle Cell Children
NCT02887118 ·Status: TERMINATED
-
Using Patient-Centered Guidelines in a Technology Platform to Improve Health Care in Adults With Sickle Cell Disease
NCT03629678 ·Status: COMPLETED ·Phase: NA
-
Sleep Respiratory Disorders Evaluation in Sickle Cell Disease Children
NCT01565954 ·Status: COMPLETED
-
Evaluation of the Hemostatic Potential in Sickle Cell Disease Patients
NCT02565082 ·Status: COMPLETED ·Phase: NA
-
Support Strategies for Parents During the First Year Following Their Child's Diagnosis of Sickle Cell Disorder
NCT06251843 ·Status: NOT_YET_RECRUITING
-
Ketorolac for Acute Vaso-Occlusive Crisis in Pediatric Sickle Cell Disease
NCT06579703 ·Status: NOT_YET_RECRUITING ·Phase: PHASE4
-
Improving Sickle Cell Disease (SCD) Care Using Web-based Guidelines
NCT03037021 ·Status: COMPLETED